Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20128708rdf:typepubmed:Citationlld:pubmed
pubmed-article:20128708lifeskim:mentionsumls-concept:C0000936lld:lifeskim
pubmed-article:20128708lifeskim:mentionsumls-concept:C0079904lld:lifeskim
pubmed-article:20128708lifeskim:mentionsumls-concept:C0917996lld:lifeskim
pubmed-article:20128708lifeskim:mentionsumls-concept:C0021376lld:lifeskim
pubmed-article:20128708lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:20128708lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:20128708lifeskim:mentionsumls-concept:C0418981lld:lifeskim
pubmed-article:20128708pubmed:issue3lld:pubmed
pubmed-article:20128708pubmed:dateCreated2010-2-12lld:pubmed
pubmed-article:20128708pubmed:abstractTextCerebral aneurysms (CAs) are the main cause of life-threatening subarachnoid hemorrhage. Given its prevalence and endpoint, CA treatment is a public health issue. Effective medical treatment of CAs is lacking because the detailed mechanisms of CA formation are incompletely understood.lld:pubmed
pubmed-article:20128708pubmed:languageenglld:pubmed
pubmed-article:20128708pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128708pubmed:citationSubsetIMlld:pubmed
pubmed-article:20128708pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128708pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128708pubmed:statusMEDLINElld:pubmed
pubmed-article:20128708pubmed:monthMarlld:pubmed
pubmed-article:20128708pubmed:issn1744-7631lld:pubmed
pubmed-article:20128708pubmed:authorpubmed-author:NishimuraMMlld:pubmed
pubmed-article:20128708pubmed:authorpubmed-author:AokiTomohiroTlld:pubmed
pubmed-article:20128708pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20128708pubmed:volume14lld:pubmed
pubmed-article:20128708pubmed:ownerNLMlld:pubmed
pubmed-article:20128708pubmed:authorsCompleteYlld:pubmed
pubmed-article:20128708pubmed:pagination265-73lld:pubmed
pubmed-article:20128708pubmed:dateRevised2011-8-25lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:meshHeadingpubmed-meshheading:20128708...lld:pubmed
pubmed-article:20128708pubmed:year2010lld:pubmed
pubmed-article:20128708pubmed:articleTitleTargeting chronic inflammation in cerebral aneurysms: focusing on NF-kappaB as a putative target of medical therapy.lld:pubmed
pubmed-article:20128708pubmed:affiliationKyoto University, Pharmacology, Kyoto 606-8507, Japan.lld:pubmed
pubmed-article:20128708pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20128708pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20128708lld:pubmed